From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...

While initially approved for diabetes, GLP-1 drugs are gaining new indications, including the large opportunity in obesity ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Measures of obesity and severe obesity are determined according to body mass index, a calculation based on height and weight.

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...